Skip to main content
SpringerLink
Log in

Dipeptidyl Peptidase-4 (DPP4) Inhibitors

  • Chapter
  • First Online:
Diabetes and Kidney Disease

  • 1002 Accesses

Abstract

Diabetes type 2 is the single most important cause of End-Stage Kidney Disease. The dipeptidyl peptidase-4 inhibitors (DPP-4is) are oral, weight-neutral hypoglycemic drugs used to treat patients with T2DM by preventing the breakdown of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, two incretins pivotal for glucose regulation. This short chapter will summarize key findings from the landmark cardiovascular safety, heart failure, and kidney disease with these agents. The basic pharmacology, mechanisms of action, adverse events, and pharmacological profile of agents approved for human use are presented in a concise fashion, and directions are given for the successful clinical use of these agents in patients with diabetes type 2 as well as the recipients of kidney transplants with diabetes and patients receiving maintenance hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roglic G, World Health Organization, editors. Global report on diabetes. World Health Organization; 2016.

    Google Scholar 

  2. Sonne DP, Hemmingsen B. Comment on American Diabetes Association. Standards of medical Care in Diabetes—2017. Diabetes Care 2017;40(Suppl. 1):S1–S135. Diabetes Care. 2017;40(7):e92–3. https://doi.org/10.2337/dc17-0299.

    Article  PubMed  Google Scholar 

  3. Saulnier P-J, Nelson RG. Burden of proof—when is kidney disease attributable to diabetes? CJASN. 2017;12(12):1917–8. https://doi.org/10.2215/CJN.10720917.

    Article  PubMed  PubMed Central  Google Scholar 

  4. de Boer IH. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532. https://doi.org/10.1001/jama.2011.861.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–23. https://doi.org/10.1038/ki.2012.401.

    Article  CAS  PubMed  Google Scholar 

  6. Nesina Prescribing Information. Accessed August 27, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf.

  7. Tradjenta Prescribing Information. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Tradjenta/Tradjenta.pdf

  8. Onglyza Prescribing Information. Accessed August 27, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022350s018lbl.pdf.

  9. Januvia Prescribing Information. Published online August 27, 2020. Accessed August 27, 2020. https://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf.

  10. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. https://doi.org/10.1056/NEJMoa1305889.

    Article  CAS  PubMed  Google Scholar 

  11. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. https://doi.org/10.1056/NEJMoa1307684.

    Article  CAS  PubMed  Google Scholar 

  12. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69. https://doi.org/10.1001/jama.2018.18269.

    Article  CAS  PubMed  Google Scholar 

  13. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352.

    Article  CAS  PubMed  Google Scholar 

  14. Kamiya H. A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease. Hemodial Int. 2017;21(1):72–83. https://doi.org/10.1111/hdi.12438.

    Article  PubMed  Google Scholar 

  15. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019;10(3) https://doi.org/10.3389/fendo.2019.00080.

  16. Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9–24. https://doi.org/10.1016/s0167-0115(99)00089-0.

    Article  CAS  PubMed  Google Scholar 

  17. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019. https://doi.org/10.1210/er.2014-1035.

    Article  CAS  PubMed  Google Scholar 

  18. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008;29(6):295–301. https://doi.org/10.1016/j.it.2008.02.010.

    Article  CAS  PubMed  Google Scholar 

  19. Yu DMT, Yao T-W, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 2010;277(5):1126–44. https://doi.org/10.1111/j.1742-4658.2009.07526.x.

    Article  CAS  PubMed  Google Scholar 

  20. Lambeir A-M, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209–94. https://doi.org/10.1080/713609354.

    Article  CAS  PubMed  Google Scholar 

  21. Varin EM, Mulvihill EE, Beaudry JL, et al. Circulating levels of soluble dipeptidyl Peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition. Cell Metab. 2019;29(2):320–334.e5. https://doi.org/10.1016/j.cmet.2018.10.001.

    Article  CAS  PubMed  Google Scholar 

  22. Baumeier C, Saussenthaler S, Kammel A, et al. Hepatic DPP4 DNA methylation associates with fatty liver. Diabetes. 2017;66(1):25–35. https://doi.org/10.2337/db15-1716.

    Article  CAS  PubMed  Google Scholar 

  23. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467–75. https://doi.org/10.1210/endo-119-4-1467.

    Article  CAS  PubMed  Google Scholar 

  24. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326(20):1316–22. https://doi.org/10.1056/NEJM199205143262003.

    Article  CAS  PubMed  Google Scholar 

  25. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–31. https://doi.org/10.2337/diab.44.9.1126.

    Article  CAS  PubMed  Google Scholar 

  26. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585–96. https://doi.org/10.1210/endo.136.8.7628397.

    Article  CAS  PubMed  Google Scholar 

  27. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2007;41(1):51–60. https://doi.org/10.1345/aph.1H459.

    Article  CAS  PubMed  Google Scholar 

  28. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–39. https://doi.org/10.1152/physrev.00034.2006.

    Article  CAS  PubMed  Google Scholar 

  29. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–47. https://doi.org/10.1111/dom.12610.

    Article  CAS  PubMed  Google Scholar 

  30. Lee Y-S, Jun H-S. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metab Clin Exp. 2014;63(1):9–19. https://doi.org/10.1016/j.metabol.2013.09.010.

    Article  CAS  PubMed  Google Scholar 

  31. Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Barranco RJ, Umpierrez GE. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios. Diabetes Ther. 2018;9(5):1775–89. https://doi.org/10.1007/s13300-018-0488-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369. https://doi.org/10.1136/bmj.e1369.

    Article  CAS  PubMed  Google Scholar 

  33. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46(11):1453–69. https://doi.org/10.1345/aph.1R041.

    Article  CAS  PubMed  Google Scholar 

  34. Uchii M, Kimoto N, Sakai M, Kitayama T, Kunori S. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2016;783:56–63. https://doi.org/10.1016/j.ejphar.2016.04.005.

    Article  CAS  PubMed  Google Scholar 

  35. Sakai M, Uchii M, Myojo K, Kitayama T, Kunori S. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;761:109–15. https://doi.org/10.1016/j.ejphar.2015.04.023.

    Article  CAS  PubMed  Google Scholar 

  36. Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular Natriuresis and increases in circulating SDF-1α1-67 in patients with type 2 diabetes. Diabetes Care. 2017;40(8):1073–81. https://doi.org/10.2337/dc17-0061.

    Article  CAS  PubMed  Google Scholar 

  37. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54(1):1–21. https://doi.org/10.1007/s40262-014-0198-2.

    Article  CAS  PubMed  Google Scholar 

  38. Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of Saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69–76. https://doi.org/10.2337/dc16-0621.

    Article  CAS  PubMed  Google Scholar 

  39. Cornel JH, Bakris GL, Stevens SR, et al. Effect of Sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304–10. https://doi.org/10.2337/dc16-1415.

    Article  CAS  PubMed  Google Scholar 

  40. Groop P-H, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610–9. https://doi.org/10.1111/dom.13041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Chen Y, Men K, Li X-F, Li J, Liu M, Fan Z-Q. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22(11):3502–14. https://doi.org/10.26355/eurrev_201806_15177.

    Article  CAS  PubMed  Google Scholar 

  42. Cheng D, Fei Y, Liu Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. PLoS One. 2014;9(10):e111543. https://doi.org/10.1371/journal.pone.0111543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Howse PM, Chibrikova LN, Twells LK, Barrett BJ, Gamble J-M. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):733–42. https://doi.org/10.1053/j.ajkd.2016.06.014.

    Article  CAS  PubMed  Google Scholar 

  44. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–6. https://doi.org/10.1053/j.gastro.2011.02.018.

    Article  CAS  PubMed  Google Scholar 

  45. Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–9. https://doi.org/10.1001/jamainternmed.2013.2720.

    Article  CAS  PubMed  Google Scholar 

  46. Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387–405. https://doi.org/10.1080/14740338.2018.1444027.

    Article  CAS  PubMed  Google Scholar 

  47. Dicembrini I, Montereggi C, Nreu B, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;159:107981. https://doi.org/10.1016/j.diabres.2019.107981.

    Article  CAS  PubMed  Google Scholar 

  48. FDA. Drug safety report. Food and DrugAdministration; 2013. Available from: https://www.fda.gov/drugs/drug-safety-and-av.

  49. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. https://doi.org/10.1161/CIRCULATIONAHA.114.010389.

    Article  CAS  PubMed  Google Scholar 

  50. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76. https://doi.org/10.1016/S0140-6736(14)62225-X.

    Article  CAS  PubMed  Google Scholar 

  51. ESC Press Releases 2015. (n.d.). Retrieved August 31, 2020, from https://www.escardio.org/The-ESC/Press-Office/Press-rel.

  52. Rosenstock J, Marx N, Neubacher D, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57. https://doi.org/10.1186/s12933-015-0215-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Huang T-L, Hsiao F-Y, Chiang C-K, Shen L-J, Huang C-F. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: a nationwide cohort study. PLoS One. 2019;14(5):e0215248. https://doi.org/10.1371/journal.pone.0215248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8–16. https://doi.org/10.1016/j.diabres.2019.02.014.

    Article  CAS  PubMed  Google Scholar 

  55. Singh AK, Singh R. Heart failure hospitalization with DPP-4 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Indian J Endocrinol Metab. 2019;23(1):128–33. https://doi.org/10.4103/ijem.IJEM_613_18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610. https://doi.org/10.1136/bmj.i610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Rai P, Zhao X, Sambamoorthi U. The Association of Joint Pain and Dipeptidyl Peptidase-4 inhibitor use among U.S. adults with Type-2 diabetes mellitus. J Pain Palliat Care Pharmacother. 2018;32(2–3):90–7. https://doi.org/10.1080/15360288.2018.1546789.

    Article  PubMed  Google Scholar 

  58. Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf. 2016;39(5):401–7. https://doi.org/10.1007/s40264-016-0399-8.

    Article  CAS  PubMed  Google Scholar 

  59. Kathe N, Shah A, Said Q, Painter JT. DPP-4 inhibitor-induced rheumatoid arthritis among diabetics: a nested case-control study. Diabetes Ther. 2018;9(1):141–51. https://doi.org/10.1007/s13300-017-0353-5.

    Article  CAS  PubMed  Google Scholar 

  60. Men P, He N, Song C, Zhai S. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis. Diabetes Metab. 2017;43(6):493–500. https://doi.org/10.1016/j.diabet.2017.05.013.

    Article  CAS  PubMed  Google Scholar 

  61. Rai P, Dwibedi N, Rowneki M, Helmer DA, Sambamoorthi U. Dipeptidyl Peptidase-4 inhibitors and joint pain: a retrospective cohort study of older veterans with type 2 diabetes mellitus. Am Health Drug Benefits. 2019;12(5):223–31.

    PubMed  PubMed Central  Google Scholar 

  62. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(12):1061–72. https://doi.org/10.1111/j.1463-1326.2012.01610.x.

    Article  PubMed  Google Scholar 

  63. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85. https://doi.org/10.1034/j.1600-6143.2003.00010.x.

    Article  PubMed  Google Scholar 

  64. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transpl. 2001;15(2):89–94. https://doi.org/10.1034/j.1399-0012.2001.150202.x.

    Article  CAS  Google Scholar 

  65. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation. 1998;65(3):380–4. https://doi.org/10.1097/00007890-199802150-00014.

    Article  CAS  PubMed  Google Scholar 

  66. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376–81. https://doi.org/10.1097/00007890-198709000-00010.

    Article  CAS  PubMed  Google Scholar 

  67. Aakhus S, Dahl K, Widerøe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transpl. 2004;18(5):596–604. https://doi.org/10.1111/j.1399-0012.2004.00235.x.

    Article  Google Scholar 

  68. Keddis MT, Bhutani G, El-Zoghby ZM. Cardiovascular disease burden and risk factors before and after kidney transplant. Cardiovasc Hematol Disord Drug Targets. 2014;14(3):185–94. https://doi.org/10.2174/1871529x14666140401112654.

    Article  CAS  PubMed  Google Scholar 

  69. Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014;2014:617638. https://doi.org/10.1155/2014/617638.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Gueler I, Mueller S, Helmschrott M, et al. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des Devel Ther. 2013;7:297–303. https://doi.org/10.2147/DDDT.S43092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation–a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14(1):115–23. https://doi.org/10.1111/ajt.12518.

    Article  CAS  PubMed  Google Scholar 

  72. Bae J, Lee MJ, Choe EY, et al. Effects of dipeptidyl Peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study. Endocrinol Metab (Seoul). 2016;31(1):161–7. https://doi.org/10.3803/EnM.2016.31.1.161.

    Article  CAS  Google Scholar 

  73. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011;92(10):e56–7. https://doi.org/10.1097/TP.0b013e3182347ea4.

    Article  PubMed  Google Scholar 

  74. Gregory S, Jenkins K. Managing care for people with diabetes undergoing dialysis: managing care for people with diabetes undergoing dialysis. J Ren Care. 2019;45(1):59–67. https://doi.org/10.1111/jorc.12266.

    Article  PubMed  Google Scholar 

  75. Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemiain end-stage renal disease patients: a review. Endocr Pract. 2017;23(3):353–62. https://doi.org/10.4158/EP161471.RA.

    Article  PubMed  Google Scholar 

  76. Information on Dipeptidyl Peptidase-4 (DPP-4) Inhibitors. Accessed August 27, 2020. https://www.fda.gov/drugs/information-drug-class/information-dipeptidyl-peptidase-4-dpp-4-inhibitors.

  77. Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ Published online May 3. 2016:i2231. https://doi.org/10.1136/bmj.i2231.

  78. Yang M, Wang L, Gu L, Yuan W. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: meta-analysis of randomized controlled trials using unadjusted data. J Diabetes. 2017;9(12):1107–17. https://doi.org/10.1111/1753-0407.12546.

    Article  CAS  PubMed  Google Scholar 

  79. Nakamura Y. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. WJD. 2015;6(6):840. https://doi.org/10.4239/wjd.v6.i6.840.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Chan S-Y, Ou S-M, Chen Y-T, Shih C-J. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease. Int J Cardiol. 2016;218:170–5. https://doi.org/10.1016/j.ijcard.2016.05.062.

    Article  PubMed  Google Scholar 

  81. Nakamura Y, Tsuji M, Hasegawa H, et al. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes: Linagliptin therapy in dialysis patients. Hemodial Int. 2014;18(2):433–42. https://doi.org/10.1111/hdi.12127.

    Article  PubMed  Google Scholar 

  82. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110. https://doi.org/10.2337/dc20-S009.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Department of Internal Medicine, Division of Nephrology, University of New Mexico School of Medicine MSC 04-2785, 1 University of New Mexico, Albuquerque, NM, USA

    Ngoc-Yen T. Pham

  2. Department of Internal Medicine, Division of Nephrology, University of New Mexico School of Medicine MSC 04-2785, 1 University of New Mexico, Albuquerque, NM, USA

    Christos Argyropoulos & Nhan Dinh

Authors
  1. Ngoc-Yen T. Pham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christos Argyropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nhan Dinh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christos Argyropoulos .

Editor information

Editors and Affiliations

  1. Section of Nephrology, University of Illinois at Chicago/Advocate Christ Medical Center,, Oak Lawn, IL, USA

    Edgar V. Lerma

  2. Nephrology Section, Tulane University, New Orleans, LA, USA

    Vecihi Batuman

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pham, NY.T., Argyropoulos, C., Dinh, N. (2022). Dipeptidyl Peptidase-4 (DPP4) Inhibitors. In: Lerma, E.V., Batuman, V. (eds) Diabetes and Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-86020-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-86020-2_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-86019-6

  • Online ISBN: 978-3-030-86020-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation